share_log

HC Wainwright & Co. Maintains Buy on Xeris Biopharma Holdings, Raises Price Target to $6

Moomoo 24/7 ·  Mar 7 06:13

HC Wainwright & Co. analyst Oren Livnat maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Buy and raises the price target from $5.5 to $6.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment